Alterations in factors involved in cholesterol homeostasis are critical in Alzheimer's disease (AD), but the stage of occurrence, their specific association, and a possible relationship with the APOE4 genotype are not clarified.
Objective
We aimed to quantify and correlate specific lipid factors in patients with different degrees of cognitive decline, namely patients with AD and patients with mild cognitive impairment due to AD (MCI-AD), carriers or non-carriers of the APOE4 genotype.
Methods
We evaluated Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), cholesterol and the oxidative metabolites 24-, 25-, 27-hydroxycholesterol (HC) in the cerebrospinal fluid (CSF) and serum of AD (n = 28) and MCI-AD (n = 27) patients.
Results
CSF and serum PCSK9 and lipids were similar, except for higher serum PCSK9 and triglycerides in MCI-AD compared to AD. In CSF, AD APOE4 carriers showed higher PCSK9 and 24-HC (+61.3%, p = 0.027 and +32.7%, p = 0.037), compared to non-carriers. There was a negative association between CSF PCSK9 and 27-HC in AD (r = −0.444, p = 0.049) and, exclusively among AD APOE4 carriers, a negative association between CSF PCSK9 and 24-HC (r = −0.786, p = 0.028). A positive correlation was observed between CSF and serum PCSK9 in AD (r = 0.520, p = 0.004), driven by APOE4 carriers (r = 0.544, p = 0.038), suggesting PCSK9 exchange between brain and periphery. A positive correlation was detected between serum and CSF 27-HC (r = 0.465, p = 0.039) in AD. None of these results were found in MCI-AD patients.
Conclusions
PCSK9 and 24-HC might be specific markers of ApoE4-associated lipid alterations in AD, possibly contributing to clinical progression in the AD continuum.
ChiariAVincetiGAdaniG, et al.Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy. Alzheimers Dement2021; 17: 81–88.
2.
HendriksSPeetoomKBakkerC, et al.Global incidence of young-onset dementia: a systematic review and meta-analysis. Alzheimers Dement2023; 19: 831–843.
3.
NiuHAlvarez-AlvarezIGuillen-GrimaF, et al.Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis. Neurologia2017; 32: 523–532.
4.
RajanKBWeuveJBarnesLL, et al.Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060). Alzheimers Dement2021; 17: 1966–1975.
5.
PapaliagkasVKalinderiKVareltzisP, et al.CSF Biomarkers in the early diagnosis of mild cognitive impairment and Alzheimer's disease. Int J Mol Sci2023; 24: 8976.
6.
TherriaultJZimmerERBenedetAL, et al.Staging of Alzheimer's disease: past, present, and future perspectives. Trends Mol Med2022; 28: 726–741.
7.
2022 Alzheimer's disease facts and figures. Alzheimers Dement2022; 18: 700–789.
8.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
9.
LiDZhangJLiuQ. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci2022; 45: 401–414.
10.
ValenzaMBiroliniGCattaneoE. The translational potential of cholesterol-based therapies for neurological disease. Nat Rev Neurol2023; 19: 583–598.
11.
GrassiSGiussaniPMauriL, et al.Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases. J Lipid Res2020; 61: 636–654.
12.
AndrewsSJRentonAEFulton-HowardB, et al.The complex genetic architecture of Alzheimer's disease: novel insights and future directions. EBioMedicine2023; 90: 104511.
13.
MarsillachJAdorniMPZimettiF, et al.HDL Proteome and Alzheimer's disease: evidence of a link. Antioxidants (Basel)2020; 9: 1224.
14.
JaafarAKTecherRChemelloK, et al.PCSK9 And the nervous system: a no-brainer?J Lipid Res2023; 64: 100426.
15.
AdorniMPRuscicaMFerriN, et al.Proprotein convertase subtilisin/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer's disease. Front Aging Neurosci2019; 11: 120.
16.
MacchiCFerriNSirtoriCR, et al.Proprotein convertase subtilisin/kexin type 9: a view beyond the canonical cholesterol-lowering impact. Am J Pathol2021; 191: 1385–1397.
17.
PapottiBAdorniMPMarchiC, et al.PCSK9 Affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer's disease. Int J Mol Sci2022; 23: 12192.
18.
BinghamBShenRKotnisS, et al.Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase. Cytometry A2006; 69: 1123–1131.
19.
SeidahNGBenjannetSWickhamL, et al.The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A2003; 100: 928–933.
20.
VilellaABodriaMPapottiB, et al.PCSK9 Ablation attenuates Abeta pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice. Brain Behav Immun2024; 115: 517–534.
21.
ChenYQTrouttJSKonradRJ. PCSK9 Is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids2014; 49: 445–455.
22.
ZimettiFCaffarraPRondaN, et al.Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer's disease. J Alzheimers Dis2017; 55: 315–320.
23.
PicardCPoirierABelangerS, et al.Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: a genetic and proteomic multi-cohort study. PloS One2019; 14: e0220254.
24.
RheaEMBanksWA. Interactions of lipids, lipoproteins, and apolipoproteins with the blood-brain barrier. Pharm Res2021; 38: 1469–1475.
25.
LeoniVMastermanTPatelP, et al.Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J Lipid Res2003; 44: 793–799.
26.
BjorkhemILutjohannDDiczfalusyU, et al.Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res1998; 39: 1594–1600.
27.
NguyenCSaint-PolJDibS, et al.25-Hydroxycholesterol In health and diseases. J Lipid Res2024; 65: 100486.
28.
OdnoshivkinaUGKuznetsovaEAPetrovAM. 25-hydroxycholesterol As a signaling molecule of the nervous system. Biochemistry (Mosc)2022; 87: 524–537.
29.
GambaPStaurenghiETestaG, et al.A crosstalk between brain cholesterol oxidation and glucose metabolism in Alzheimer's disease. Front Neurosci2019; 13: 556.
30.
LeoniVCacciaC. Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid. Biochem Pharmacol2013; 86: 26–36.
31.
WangHLWangYYLiuXG, et al.Cholesterol, 24-hydroxycholesterol, and 27-hydroxycholesterol as surrogate biomarkers in cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease: a meta-analysis. J Alzheimers Dis2016; 51: 45–55.
32.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
33.
TondelliMBedinRChiariA, et al.Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study. Clin Chem Lab Med2015; 53: 453–460.
34.
TurriMContiEPavanelloC, et al.Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer's disease. Alzheimers Res Ther2023; 15: 95.
35.
YassineHNFengQChiangJ, et al.ABCA1-mediated Cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer's disease. J Am Heart Assoc2016; 5: e002886.
36.
ChenYHeYHanJ, et al.Blood-brain barrier dysfunction and Alzheimer's disease: associations, pathogenic mechanisms, and therapeutic potential. Front Aging Neurosci2023; 15: 1258640.
37.
Loera-ValenciaRGoikoleaJParrado-FernandezC, et al.Alterations in cholesterol metabolism as a risk factor for developing Alzheimer's disease: potential novel targets for treatment. J Steroid Biochem Mol Biol2019; 190: 104–114.
38.
YinF. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J2023; 290: 1420–1453.
39.
ArnaudLBenechPGreethamL, et al.APOE4 Drives inflammation in human astrocytes via TAGLN3 repression and NF-kappaB activation. Cell Rep2022; 40: 111200.
40.
RodaARMontoliu-GayaLVillegasS. The role of apolipoprotein E isoforms in Alzheimer's disease. J Alzheimers Dis2019; 68: 459–471.
41.
MontagneANationDASagareAP, et al.APOE4 Leads to blood-brain barrier dysfunction predicting cognitive decline. Nature2020; 581: 71–76.
42.
HallidayMRRegeSVMaQ, et al.Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab2016; 36: 216–227.
43.
ArunsakBPratchayasakulWAmputP, et al.Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats. Arch Biochem Biophys2020; 689: 108470.
44.
HuZLYuanYQTongZ, et al.Reexamining the causes and effects of cholesterol deposition in the brains of patients with Alzheimer's disease. Mol Neurobiol2023; 60: 6852–6868.
45.
KoYABillheimerJTLyssenkoNN, et al.Apoj/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer's disease. Alzheimers Res Ther2022; 14: 194.
46.
DunkMMLiJLiuS, et al.Associations of dietary cholesterol and fat, blood lipids, and risk for dementia in older women vary by APOE genotype. Alzheimers Dement2023; 19: 5742–5754.
47.
Frikke-SchmidtR. Context-dependent and invariant associations between APOE genotype and levels of lipoproteins and risk of ischemic heart disease: a review. Scand J Clin Lab Invest2000; 233: 3–25.
48.
ZimettiFAdorniMPMarsillachJ, et al.Connection between the altered HDL antioxidant and anti-inflammatory properties and the risk to develop Alzheimer's disease: a narrative review. Oxid Med Cell Longev2021; 2021: 6695796.
49.
KheraAVQamarAReillyMP, et al.Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol2015; 115: 178–182.
50.
GambaPGiannelliSStaurenghiE, et al.The controversial role of 24-S-hydroxycholesterol in Alzheimer's disease. Antioxidants (Basel)2021; 10: 740.
51.
SchonknechtPLutjohannDPantelJ, et al.Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett2002; 324: 83–85.
52.
ZulianiGDonnorsoMPBosiC, et al.Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study. BMC Neurol2011; 11: 121.
53.
BretillonLSidenAWahlundLO, et al.Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett2000; 293: 87–90.
54.
DiasIHKShokrHShephardF, et al.Oxysterols and oxysterol sulfates in Alzheimer's disease brain and cerebrospinal fluid. J Alzheimers Dis2022; 87: 1527–1536.
55.
GambaPTestaGGargiuloS, et al.Oxidized cholesterol as the driving force behind the development of Alzheimer's disease. Front Aging Neurosci2015; 7: 119.
56.
TestaGStaurenghiEZerbinatiC, et al.Changes in brain oxysterols at different stages of Alzheimer's disease: their involvement in neuroinflammation. Redox Biol2016; 10: 24–33.
57.
BogdanovicNBretillonLLundEG, et al.On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett2001; 314: 45–48.
58.
SoderoAO. 24S-hydroxycholesterol: cellular effects and variations in brain diseases. J Neurochem2021; 157: 899–918.
59.
PapassotiropoulosALutjohannDBagliM, et al.24S-hydroxycholesterol In cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res2002; 36: 27–32.
60.
JeitnerTMVoloshynaIReissAB. Oxysterol derivatives of cholesterol in neurodegenerative disorders. Curr Med Chem2011; 18: 1515–1525.
61.
SobatiSShakouriAEdalatiM, et al.PCSK9: a key target for the treatment of cardiovascular disease (CVD). Adv Pharm Bull2020; 10: 502–511.
62.
SunLPSeemannJGoldsteinJL, et al.Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: insig renders sorting signal in scap inaccessible to COPII proteins. Proc Natl Acad Sci U S A2007; 104: 6519–6526.
63.
StaurenghiELeoniVLo IaconoM, et al.Apoe3 vs. ApoE4 astrocytes: a detailed analysis provides new insights into differences in cholesterol homeostasis. Antioxidants (Basel)2022; 11: 2168.
64.
LutjohannDStellaardFBolukbasiB, et al.Anti-PCSK 9 antibodies increase the ratios of the brain-specific oxysterol 24S-hydroxycholesterol to cholesterol and to 27-hydroxycholesterol in the serum. Br J Clin Pharmacol2021; 87: 4252–4261.
65.
TijmsBMVromenEMMjaavattenO, et al.Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging2024; 4: 33–47.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
